{"id":19159,"date":"2024-04-05T19:22:32","date_gmt":"2024-04-05T22:22:32","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/"},"modified":"2024-04-05T19:22:32","modified_gmt":"2024-04-05T22:22:32","slug":"imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/","title":{"rendered":"IMVIGOR 011 \u2013 BO42843 &#8211; C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco &#8211; adjuv\u00e2ncia"},"content":{"rendered":"<p><span data-contrast=\"auto\">Atezolizumabe versus placebo na adjuv\u00e2ncia.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">&nbsp;<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Popula\u00e7\u00e3o: <\/span><\/b><span data-contrast=\"auto\">Carcinoma urotelial m\u00fasculo-invasivo da bexiga confirmado histologicamente; cistectomia radical com margem cir\u00fargica negativa; recupera\u00e7\u00e3o total da cistectomia e a admiss\u00e3o dentro de 24 semanas ap\u00f3s a cistectomia; aus\u00eancia de doen\u00e7a residual e aus\u00eancia de met\u00e1stase; permitido tratamento com radia\u00e7\u00e3o e\/ou quimioterapia neoadjuvante.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:0,&quot;335559740&quot;:240}\">&nbsp;<\/span><\/p>\n<p><span class=\"NormalTextRun SCXW99976888 BCX0\">ClinicalTrials.gov:<\/span> <span class=\"NormalTextRun SCXW99976888 BCX0\">NCT04660344<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Atezolizumabe versus placebo na adjuv\u00e2ncia.&nbsp; Popula\u00e7\u00e3o: Carcinoma urotelial m\u00fasculo-invasivo da bexiga confirmado histologicamente; cistectomia radical com margem cir\u00fargica negativa; recupera\u00e7\u00e3o total da cistectomia e a admiss\u00e3o dentro de 24 semanas ap\u00f3s a cistectomia; aus\u00eancia de doen\u00e7a residual e aus\u00eancia de met\u00e1stase; permitido tratamento com radia\u00e7\u00e3o e\/ou quimioterapia neoadjuvante.&nbsp; ClinicalTrials.gov: NCT04660344<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19159","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMVIGOR 011 \u2013 BO42843 - C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco - adjuv\u00e2ncia - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMVIGOR 011 \u2013 BO42843 - C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco - adjuv\u00e2ncia - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Atezolizumabe versus placebo na adjuv\u00e2ncia.&nbsp; Popula\u00e7\u00e3o: Carcinoma urotelial m\u00fasculo-invasivo da bexiga confirmado histologicamente; cistectomia radical com margem cir\u00fargica negativa; recupera\u00e7\u00e3o total da cistectomia e a admiss\u00e3o dentro de 24 semanas ap\u00f3s a cistectomia; aus\u00eancia de doen\u00e7a residual e aus\u00eancia de met\u00e1stase; permitido tratamento com radia\u00e7\u00e3o e\/ou quimioterapia neoadjuvante.&nbsp; ClinicalTrials.gov: NCT04660344\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\\\/\",\"url\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\\\/\",\"name\":\"IMVIGOR 011 \u2013 BO42843 - C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco - adjuv\u00e2ncia - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2024-04-05T22:22:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IMVIGOR 011 \u2013 BO42843 &#8211; C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco &#8211; adjuv\u00e2ncia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMVIGOR 011 \u2013 BO42843 - C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco - adjuv\u00e2ncia - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/","og_locale":"pt_BR","og_type":"article","og_title":"IMVIGOR 011 \u2013 BO42843 - C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco - adjuv\u00e2ncia - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Atezolizumabe versus placebo na adjuv\u00e2ncia.&nbsp; Popula\u00e7\u00e3o: Carcinoma urotelial m\u00fasculo-invasivo da bexiga confirmado histologicamente; cistectomia radical com margem cir\u00fargica negativa; recupera\u00e7\u00e3o total da cistectomia e a admiss\u00e3o dentro de 24 semanas ap\u00f3s a cistectomia; aus\u00eancia de doen\u00e7a residual e aus\u00eancia de met\u00e1stase; permitido tratamento com radia\u00e7\u00e3o e\/ou quimioterapia neoadjuvante.&nbsp; ClinicalTrials.gov: NCT04660344","og_url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/","url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/","name":"IMVIGOR 011 \u2013 BO42843 - C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco - adjuv\u00e2ncia - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2024-04-05T22:22:32+00:00","breadcrumb":{"@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/imvigor-011-bo42843-cancer-de-bexiga-musculo-invasivo-de-alto-risco-adjuvancia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"IMVIGOR 011 \u2013 BO42843 &#8211; C\u00e2ncer de bexiga m\u00fasculo-invasivo de alto risco &#8211; adjuv\u00e2ncia"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}